LUCENTIS Drug Profile
✉ Email this page to a colleague
Summary for Tradename: LUCENTIS
| Patents: | 9 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for LUCENTIS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LUCENTIS |
Recent Clinical Trials for LUCENTIS
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Affiliated Hospital of Nantong University | Phase 3 |
| Wake Forest University Health Sciences | Phase 4 |
| Shanghai Henlius Biotech | Phase 3 |
Recent Litigation for LUCENTIS
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. | 2020-06-19 |
| Cytiva Sweden AB v. Bio-Rad Laboratories, Inc. | 2018-11-29 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Regeneron Pharmaceuticals, Inc. | 2021-04-16 |
| Regeneron Pharmaceuticals, Inc. | 2020-07-16 |
Pharmacology for LUCENTIS
| Mechanism of Action | Vascular Endothelial Growth Factor Inhibitors |
| Established Pharmacologic Class | Vascular Endothelial Growth Factor Inhibitor |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for LUCENTIS Derived from Brand-Side Litigation
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | See Plans and Pricing | 2035-11-05 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | See Plans and Pricing | 2028-07-08 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | See Plans and Pricing | 2034-03-14 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
2) High Certainty: US Patents for LUCENTIS Derived from Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for LUCENTIS Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | See Plans and Pricing | 2032-05-15 | Patent claims search |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | See Plans and Pricing | 2033-03-11 | Patent claims search |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | See Plans and Pricing | 2033-08-12 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
